医学
奥西默替尼
肺癌
内科学
表皮生长因子受体
肿瘤科
进行性疾病
胃肠病学
入射(几何)
癌症
埃罗替尼
疾病
物理
光学
作者
A. Schuler,J. Huser,Sabine Schmid,Sämi Schär,Amina Scherz,Oliver Gautschi,Laetitia Mauti,Thomas von Briel,Christine Waibel,Luciano Wannesson,J. Pankovics,Michaela Mark,Sacha I. Rothschild,Alfredo Addeo,Wolf-Dieter Janthur,Marco Siano,Laura Amanda Boos,Christian Britschgi,Martin Früh
出处
期刊:Lung Cancer
[Elsevier]
日期:2024-01-01
卷期号:187: 107427-107427
被引量:1
标识
DOI:10.1016/j.lungcan.2023.107427
摘要
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for patients with EGFR mutated non-small cell lung cancer as first-line treatment. However, treatment resistance inevitably emerges and may present as oligo-progressive disease (OPD) or systemic progressive disease (SPD). The incidence of OPD on first-line osimertinib is unknown.We retrospectively analyzed patients who received first-line osimertinib at 13 Swiss centers. The rate of OPD (PD in ≤ 5 lesions) and treatment outcomes were analyzed.The median age of the 148 patients was 68.2 years (range. 38.0-93.3). There were 62 % females, 83 % with a PS ≤ 1, 59 % never smokers, 57 % of patients with an EGFR exon 19 deletion and 37 % with EGFR p.L858R exon 21. 77 % experienced OPD. Median overall survival (OS) was 51.6 months (95 % CI, 38.4-65.0). Median progression-free survival (PFS) was 19.2 (95 % CI, 14.3-23.5) and 8.7 (95 % CI, 2.8-15.6) months for patients with common and uncommon EGFR mutations. Patients with OPD compared to SPD had a significantly longer time to treatment failure and longer OS of (22.9 vs. 10.8 months, p < 0.001 and 51.6 vs. 26.4 months, p = 0.004, respectively). The most common organ sites of PD were lung (62 %), brain (30 %), lymph nodes (30 %), bone (27 %) and pleura (27 %). Twenty-six patients (45 %) with OPD received local ablative treatment (LAT). The OS of OPD patients with LAT was 60.0 (95 % CI, 51.6-NA) vs. 51.4 (95 % CI 38.4-65.3) months (p = 0.43) without LAT.The rate of OPD of patients receiving first line osimertinib was 77 %. Patients with OPD had a significantly better OS compared to patients with SPD (51.6 vs. 26.4 months). Patients with OPD receiving LAT had the longest median OS (60.0 months).
科研通智能强力驱动
Strongly Powered by AbleSci AI